Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
	Dec. 30, 2011	Dec. 31, 2010
Cash flows from operating activities:
Net loss	$ (1,048,000)	$ (1,320,000)
Adjustments to reconcile net loss to net cash provided by operating activities
Depreciation	806,000	707,000
Amortization	1,028,000	1,223,000
Stock based compensation expense	480,000	158,000
Change in fair value of warrant liability	(719,000)	186,000
Loss on debt extinguishment		318,000
Changes in operating assets and liabilities:
Accounts receivable - net	665,000	(1,507,000)
Inventories	451,000	(1,119,000)
Prepaid expenses and other assets	(44,000)	(245,000)
Accounts payable and accrued expenses	(1,468,000)	1,904,000
Net cash provided by operating activities	151,000	305,000
Cash flows from investing activities:
Capital expenditures	(543,000)	(937,000)
Change in restricted cash	500,000
Patent expenditures	(159,000)	(216,000)
Net cash used in investing activities	(202,000)	(1,153,000)
Cash flows from financing activities:
Proceeds on bank line of credit		600,000
Payments on bank line of credit	(494,000)
Proceeds on bank term loan	998,000
Payments on bank term loan	(727,000)	(325,000)
Payments on MEDC/MSF term loan	(425,000)	(129,000)
Payments on related parties debt	(449,000)	(151,000)
Proceeds from issuance of common stock		279,000
Proceeds from exercise of stock options	25,000
Net cash provided by (used in) financing activities	(1,072,000)	274,000
Net decrease in cash and cash equivalents	(1,123,000)	(574,000)
Cash and cash equivalents at beginning of period	4,744,000	1,762,000
Cash and cash equivalents at end of period	3,621,000	1,188,000
Supplemental disclosure of cash flow information:
Cash paid for income taxes
Cash paid for interest	146,000	223,000
Non-cash financing activities:
Conversion of accrued MEDC loan interest to common stock		$ 562,000